Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients

  • End date
    May 25, 2022
  • participants needed
  • sponsor
    Lorenza Scotti
Updated on 25 January 2021
hematologic malignancy


Impact of the Comprehensive Geriatric Assessment on the Quality of Life of elderly onco-hematologic patients' candidates for complex antitumoral therapies: clinical and biological correlatives


The screenings for the next 2 decades indicate an exponential increase in the incidence of neoplastic diseases in the elderly population. In order to successfully balance effectiveness and low toxicity of immunochemotherapy, a treatment personalisation based on an objective evaluation of fitness is therefore needed. The use of geriatric screening is a first step to rationalize decisions in this regard, the G8 tool has demonstrated the ability to identify patients and mostly to objectively separate elderly fragile patients from those who are fit. In that consideration, the individualization of the anticancer treatment based on a Comprehensive Geriatric Assessment (CGA) is desirable in elderly fragile patients with solid or haematological malignancy. Cancer mortality is constantly increasing after 65 years and the consequent increase in life expectancy favour the processes of cellular senescence. In this context G8 fragility assessment will take place in the screening test and by using the EORTC QLQ-C30C questionnaire to assess quality of life (QoL). The evaluation of senescent cells will be done by real-time PCR. Our aims are i) to evaluate the impact of the CGA on the QoL of elderly onco-haematological patients, candidates for complex therapies, that resulted as fragile at the G8 geriatric screening and ii) to evaluate the senescent cells in the peripheral blood of the patients enrolled in the study. The study is expected to contribute to precision medicine management of elderly patients and refine the therapeutic stratifications.

Condition Hematologic Malignancy, Blood Cancer, Hematologic Cancer, Hematologic Neoplasms, Blood disorder, Hematological Disorders, Solid Tumors, Solid Tumor, Solid Neoplasm, Elderly Patients, Solid Tumour, Blood Cancer, Hematologic Cancer, Hematological Disorders, Hematologic Neoplasms, Hematologic Malignancies, Elderly, Solid Tumor, Elderly, Hematologic Malignancies, Elderly, Solid Tumor, Elderly, hematological malignancy, hematologic malignancies, hematological tumor, haematological malignancy, hematological malignancies
Clinical Study IdentifierNCT04478916
SponsorLorenza Scotti
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Patients aged 65 years
Diagnosis of solid or hematologic cancer
Patients who are candidates for a first line therapy for advanced disease to be treated with biological target drugs, or candidates for integrated radiotherapy
Patient with G8 scores 14/17

Exclusion Criteria

Patients aged less than 65 years
Patients who have received or currently in treatment for solid or hematologic cancer
Patient with G8 scores more than 14/17
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note